Kaposi’s Sarcoma in Kidney Graft Recipients Treated with Low Doses of Cyclosporine
Kaposi’s sarcoma (KS) is a neoplastic disease of endothelial cells, which accounts for some 3% of organ transplantation malignancies, and it is also common in HIV infection. KS incidence seems increased with Cyclosporine (CSA) therapy, as compared with conventional immunosuppression (1, 2). In our unit, 4 out of 150 CSA-treated recipients developed KS, while no other malignancies have been recorded. This occurred despite a low-dose CSA regimen (3), as compared with the absence of neoplasia in other 150 patients receiving conventional treatment.The clinical features of our KS cases were reviewed.
KeywordsOral Candidiasis Conventional Immunosuppression Multiple Blood Transfusion sterOid Resistant Rejection Kidney Graft Recipient
Unable to display preview. Download preview PDF.
- 4).Contu L et al:In Cerimele D (ed): Kaposi’s sarcoma Spectrum, Ph. 1985, 29.Google Scholar
- 5).Scorza Smeraldi R, Fabio G, Lazzarin A, et al: Lancet 2: 1187, 1987.Google Scholar
- 6).Levine AS: In Friedman-Kien AE, Laubensteìn LJ (eds): The epidemic of Kaposi sarcoma and opportunistic infections. Masson, N. Y. 1984, p 7.Google Scholar